
    
      This is a randomized single blind study where subjects will be allocated to undergo one of
      the 4 protocols. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20
      minutes prior to the first endothelial function measurement.

      This medication acts by reducing the activity of nerves believed to be involved in the
      conditioning process. The placebo pill, designed to have no effect, will be used as a
      comparison. Comprehensive tests will occur which include Microneurography, Endothelial
      function ,Blood Sampling, Temporary block of arm blood flow and Remote conditioning
    
  